The German Health Insurance fund has paid out close to $55 million in reimbursement for medical cannabis last quarter

In the first quarter of 2023, insurance reimbursements for medical cannabinoid products in Germany continued to grow, illustrating the ongoing gradual expansion of the country’s cannabis industry, which now ranks among the largest globally.

This period’s reimbursement reached approximately 50.9 million euros ($55.6 million), as indicated by the most recent data from the German National Association of Statutory Health Insurance Funds (GKV-Spitzenverband). This marks a 6.5% increase compared to the same period in the previous year. However, there was a minor decline compared to the fourth quarter of 2022. During this quarter, nearly 99,000 prescriptions were filled.

Within the market segments, the dried-flower segment accounted for 21.1 million euros, while finished pharmaceutical products, encompassing items like Sativex and Epidolex, recorded sales of 13.1 million euros.

For context, during the same quarter, Canada’s regulated cannabis market registered medical cannabis sales worth 98 million Canadian dollars ($72 million), per Statistics Canada’s data. It’s important to note that the German reimbursement figures do not encompass private prescription sales paid directly by patients. Consequently, the actual medical cannabis sales in Germany exceeded the reported 55.6 million euros, although an exact figure remains unavailable.

Read their full report at

Primary Sponsor


Karma Koala Podcast

Top Marijuana Blog